Supplementary Materials for the Fiscal Year Ending March 2026 Financial Results

Overview of Financial Results

Consolidated revenue for the fiscal year ending March 2026 reached 2,139.2 billion yen, an 11.9% increase year-over-year. Operating income rose sharply to 382.6 billion yen (up 832.4% YoY), and net income increased significantly to 291.6 billion yen (up 474.6% YoY). On a core basis, revenue was also 2,139.2 billion yen, operating income was 555.7 billion yen (up 41.6% YoY), and net income was 424.4 billion yen (up 43.5% YoY), reflecting solid performance. Regionally, the U.S. recorded 940.2 billion yen in sales (up 8.5% YoY), Japan posted 289.0 billion yen (up 8.2% YoY), Established Markets 563.6 billion yen (up 16.1% YoY), and China 101.5 billion yen (up 29.6% YoY), achieving growth across all areas. Sales of key products also grew substantially, with strategic flagship products such as PADCEV, VYLOY, and IZERVAY performing strongly.

Outlook and Pipeline Updates

The full-year forecast for the fiscal year ending March 2027 anticipates revenue of 2,220.0 billion yen (up 3.8% YoY), operating income of 395.0 billion yen (up 3.2% YoY), and net income of 300.0 billion yen (up 2.9% YoY). Research and development expenses are expected to increase, with proactive advancement in new drug development. The development stages of key strategic products span multiple indications, including clinical trials underway for diseases such as cisplatin-eligible muscle-invasive bladder cancer and acute myeloid leukemia. Additionally, the pipeline is being strengthened by incorporating cutting-edge technologies like digital health and gene therapy. Foreign exchange fluctuations positively impacted sales revenue by 30.1 billion yen and core operating income by 16.8 billion yen.